



October 27, 2017

Br. 2

Re. License No. 06-28799-01

03032976

Licensing Assistance Team  
Division of Nuclear Materials Safety  
U.S. Nuclear Regulatory Commission, Region I  
2100 Renaissance Boulevard, Suite 100  
King of Prussia, Pa 19406-2713

To Mr. Dennis Lawyer:

Alexion Pharmaceuticals, Inc. requests the following administrative change to the above reference license:

Effective upon receipt of this letter, Dr. Sharon Barr, Ph.D, Executive Director Research, has assumed the role of Institutional Official, replacing Dr. Stephen Uden, Senior Vice President Research. Dr. Barr is a member of the Research and Development Leadership Team of Alexion Pharmaceuticals and heads all Research functions.

Thank you for your time and assistance in the matter. If you have any questions, or require additional information please do not hesitate to contact Joseph Paradiso, CSP, RSO at [joseph.paradiso@alexion.com](mailto:joseph.paradiso@alexion.com).

Sincerely,

John Orloff, M.D.  
Executive Vice President  
Head of Research and Development



**ACKNOWLEDGEMENT - RECEIPT OF CORRESPONDENCE**

<b>Name and Address of Applicant and/or Licensee</b>  Joseph J. Paradiso Radiation Safety Officer Alexion Pharmaceuticals, Inc. 100 College Street New Haven, Connecticut 06510	<b>Date</b> November 14, 2017
	<b>License Number(s)</b> 06-28799-01
	<b>Mail Control Number(s)</b> 601616
	<b>Licensing and/or Technical Reviewer or Branch</b> Commercial, Industrial, R&D, and Academic Branch

This is to acknowledge receipt of your:  Letter and/or  Application Dated: October 27, 2017

The initial processing, which included an administrative review, has been performed.  Notification  
 Amendment  Termination  New License  Renewal

There were no administrative omissions identified during our initial review.

This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.

Your application for a new NRC license did not include your taxpayer identification number. Please complete and submit NRC Form 531, Request for Taxpayer Identification Number, located at the following link: <http://www.nrc.gov/reading-rm/doc-collections/forms/nrc531.pdf>  
 Follow the instructions on the form for submission.

The following administrative omissions have been identified:

Your application has been assigned the above listed MAIL CONTROL NUMBER. When calling to inquire about this action, please refer to this control number. Your application has been forwarded to a technical reviewer. Please note that the technical review, which is normally completed within 180 days for a renewal application (90 days for all other requests), may identify additional omissions or require additional information. If you have any questions concerning the processing of your application, our contact information is listed below:

**Region I**  
 U. S. Nuclear Regulatory Commission  
 Division of Nuclear Materials Safety  
 2100 Renaissance Boulevard, Suite 100  
 King of Prussia, PA 19406-2713  
 (610) 337-5260, (610) 337-5313,  
 (610) 337-5398, (610) 337-5239